IGEN ups the stakes in dispute with Roche Diagnostics
This article was originally published in Clinica
Executive Summary
IGEN International is taking steps to "maximise the value of its proprietary ORIGEN technology" both before and after the expected final judgement relating to its dispute with Roche Diagnostics over the licensing of the electro-chemiluminescence technology to Roche.